May 9, 2017- Araim Pharmaceuticals’ Cibinetide (ARA 290) Regenerates Small Nerve Fibers and Improves Neuropathic Clinical Symptoms in the Orphan Disease of Sarcoidosis

November 28, 2016 – ARA 290 Obtains European Union Orphan Drug Designation for Prevention of Graft Loss in Pancreatic Islet Transplantation

August 08, 2016Araim Pharmaceuticals Announces Appointment of Ferdinand C. Breedveld, M.D. as Chairman of the Board

July 25, 2016Araim Pharmaceuticals Obtains Fourth Orphan Designation: ARA 290 Obtains US Orphan Drug Designation for Treatment to Increase Survival and Improve Functioning of Pancreatic Islets Following Transplantation

July 5, 2016 Araim Pharmaceuticals Receives Orphan Drug Designation from the US FDA for ARA 290 for the Treatment of Sarcoidosis

May 10, 2016Queen’s University Belfast to study the Innate Repair Activator ARA 290 in Diabetic Macular Edema

December 31, 2015 – Araim Pharmaceuticals announces a strategic partnership with Vault Bioventures to support development and commercialization of ARA 290 as well as other peptides within a novel family

December 22, 2015Araim Pharmaceuticals’ ARA 290 significantly improves islet cell function following islet cell transplantation in a model of Type 1 diabetes

December 16, 2014Molecular Medicine Issues 20th Anniversary Edition: Journal Focuses on the legacy and impact of Anthony Cerami’s groundbreaking work on diabetes

December 15, 2014New Study Published in Molecular Medicine Reports That Novel Agent Decreases Neuropathic Pain in Patients with Type 2 Diabetes

October 28, 2014 Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290 for the Treatment of Sarcoidosis-associated Small Fiber Neuropathy

October 10, 2013Araim Pharmaceuticals’ ARA 290, a Peptide Engineered to Activate Innate Repair, Receives Orphan Drug Designation from the European Commission